Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
12 Results for "
Caki-1
" in MedChemExpress (MCE) Product Catalog:
Products (12)
12 Results for "Caki-1" in MCE Product Catalog:
7
1
1 Cited Publications
HC-5404-Fu is an orally active PERK inhibitor with an IC50 of 0.001 μM against human PERK. HC-5404-Fu blocks PERK activation induced by VEGFR-TKI and disrupts the adaptive stress response triggered by VEGFR-TKI. HC-5404-Fu enhances anti-angiogenic effects by inhibiting newly formed and mature tumor blood vessels in renal cell carcinoma models. HC-5404-Fu can be used in research related to renal cell carcinoma [1].
Synonyms: RX-5902
Target:
Research Areas:
Supinoxin (RX-5902) is an orally active inhibitor of phosphorylated-p68 RNA helicase (P-p68) and a potent first-in-class anti-cancer agent. Supinoxin interacts with Y593 phosphorylated-p68 and attenuates the nuclear shuttling of β-catenin. Supinoxin induces cell apoptosis and inhibits growth of TNBC cancer cell lines with IC50s ranging from 10 nM to 20 nM [1] .
Synonyms: Ro-31-7453
MKC-1 (Ro-31-7453) is an orally active and potent cell cycle inhibitor with broad antitumor activity. MKC-1 inhibits the Akt/mTOR pathway. MKC-1 arrests cellular mitosis and induces cell apoptosis by binding to a number of different cellular proteins including tubulin and members of the importin β family [1] .
Cat. No.: HY-161865
Antitumor agent-180 (Compound 13a) is an inhibitor for BUB1 mitotic checkpoint serine/threonine kinase B (BUB1B). Antitumor agent-180 inhibits the proliferation of ccRCC cell Caki-1 with IC50 of 2.047 µM. Antitumor agent-180 induces necrosis and apoptosis in Caki-1 [1].
Cat. No.: HY-172089
CAS No.: 3105969-02-3
TG101209 analog 1 (Compound 8h) is an inhibitor for BUB1B with an IC50 of 10.36 μM. TG101209 analog 1 exhibits cytotoxicity (IC50 for Caki-1 is 1.347 μM), induce necrosis and apoptosis [1].
Cat. No.: HY-158048
CAS No.: 3094059-54-5
UNC9036 is a STING PROTAC degrader with a DC50 value of 227 nM. UNC9036 binds to and activates STING, recruits the VHL E3 ligase to target phosphorylated STING for ubiquitination and proteasomal degradation. UNC9036 inhibits downstream innate immune signaling events triggered by cytoplasmic DNA sensing, including IRF3 phosphorylation. UNC9036 reduces the antiviral response of cells infected with HSV-1. UNC9036 can be used in the research of renal cell carcinoma [1].
Cat. No.: HY-162141
CAS No.: 2755794-94-4
MD102 is an orally active transglutaminase 2 (TG2) inhibitor with an IC50 of 0.35 μM. MD102 binds to the β-sandwich domain of TG2, disrupts the interaction between TG2 and p53, stabilizes p53, and reduces the activity of p-AKT and p-mTOR signaling pathways. MD102 induces cell apoptosis and inhibits tumor growth. MD102 can be used for the research of renal cell carcinoma [1].
Cat. No.: HY-13691R
CAS No.: 125313-92-0
Synonyms: Ro-31-7453 (Standard)
Research Areas:
MKC-1 (Standard) is the analytical standard of MKC-1. This product is intended for research and analytical applications. MKC-1 (Ro-31-7453) is an orally active and potent cell cycle inhibitor with broad antitumor activity. MKC-1 inhibits the Akt/mTOR pathway. MKC-1 arrests cellular mitosis and induces cell apoptosis by binding to a number of different cellular proteins including tubulin and members of the importin β family [1] .
Cat. No.: HY-146230
CAS No.: 2439096-06-5
VEGFR-2-IN-26 (compound 5h) is a highly potent VEGFR-2 inhibitor with an IC50 value of 15.5 nM. VEGFR-2-IN-26 has good antiproliferative activity against the leukemic, non-small lung, CNS, ovarian, renal, prostate and breast cancer cells [1].
Cat. No.: HY-W470101
CAS No.: 861212-49-9
Research Areas:
HIF-2α-IN-17 is a selective hypoxia-inducible factor 2α (HIF2α) inhibitor that binds to the PAS-B domain of HIF2α. HIF-2α-IN-17 disrupts the interaction between HIF2α and the molecular chaperone Hsp70, leading to proteasomal degradation of HIF2α. HIF-2α-IN-17 exhibits antitumor activity and induces apoptosis in cancer cells. HIF-2α-IN-17 is applicable for research on cancers such as clear cell renal cell carcinoma [1].
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
